Bayer Withheld Trasylol Study Findings
October 2006
Last month, Bayer scientists met with the Food and Drug Administration (FDA) to discuss their heart-surgery drug, Trasylol, and its possible risks. But Bayer failed to mention that they already conducted a large study on the drug and the results showed an increase in the risk of death and stroke.
The study performed by Bayer evaluated 67,000 patient records. Of those, 30,000 received Trasylol and the rest got a different drug. The patients who received Trasylol had a greater risk of kidney failure, heart attack and stroke. A researcher involved in it alerted the FDA about the drug’s side-effects.
The FDA is evaluating the new study to find out whether the results will change the agency’s advice on the drug. Trasylol is given to patients prior to surgery to reduce the risk of blood loss and the need for transfusions in patients undergoing heart bypass surgery.
Have You Suffered Injuries Due to the Drug Trasylol? Contact Us Now For a Free Evaluation of Your Legal Case.
Call us toll-free at 1-866-943-3427 or get online legal help, and we'll give you a free evaluation of your claim.
Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Ohio and West Virginia and we associate with experienced attorneys in other states. In addition, all drug-related litigation involves co-counsel.
Source: “FDA Says Bayer Failed to Reveal Drug Risk Study.” By Gardiner
Harris. The New York Times. September 30, 2006.
